144 related articles for article (PubMed ID: 35498548)
1. Applying polypharmacology approach for drug repurposing for SARS-CoV2.
Jamir E; Sarma H; Priyadarsinee L; Nagamani S; Kiewhuo K; Gaur AS; Rawal RK; Murugan NA; Subramanian V; Sastry GN
J Chem Sci (Bangalore); 2022; 134(2):57. PubMed ID: 35498548
[TBL] [Abstract][Full Text] [Related]
2. Polypharmacology guided drug repositioning approach for SARS-CoV2.
Jamir E; Sarma H; Priyadarsinee L; Kiewhuo K; Nagamani S; Sastry GN
PLoS One; 2023; 18(8):e0289890. PubMed ID: 37556478
[TBL] [Abstract][Full Text] [Related]
3. Identification of promising drug candidates against NSP16 of SARS-CoV-2 through computational drug repurposing study.
Vijayan V; Pant P; Vikram N; Kaur P; Singh TP; Sharma S; Sharma P
J Biomol Struct Dyn; 2021 Oct; 39(17):6713-6727. PubMed ID: 32741322
[TBL] [Abstract][Full Text] [Related]
4. Identification of promising antiviral drug candidates against non-structural protein 15 (NSP15) from SARS-CoV-2: an
Khan RJ; Jha RK; Singh E; Jain M; Amera GM; Singh RP; Muthukumaran J; Singh AK
J Biomol Struct Dyn; 2022 Jan; 40(1):438-448. PubMed ID: 32885740
[TBL] [Abstract][Full Text] [Related]
5. Repurposing FDA-approved drugs to fight COVID-19 using
Mahdian S; Zarrabi M; Panahi Y; Dabbagh S
Inform Med Unlocked; 2021; 23():100541. PubMed ID: 33649734
[TBL] [Abstract][Full Text] [Related]
6. Drug Repurposing Approach against Novel Coronavirus Disease (COVID-19) through Virtual Screening Targeting SARS-CoV-2 Main Protease.
Chowdhury KH; Chowdhury MR; Mahmud S; Tareq AM; Hanif NB; Banu N; Reza ASMA; Emran TB; Simal-Gandara J
Biology (Basel); 2020 Dec; 10(1):. PubMed ID: 33374717
[TBL] [Abstract][Full Text] [Related]
7.
Gurung AB
Gene Rep; 2020 Dec; 21():100860. PubMed ID: 32875166
[TBL] [Abstract][Full Text] [Related]
8. Identification of saquinavir as a potent inhibitor of dimeric SARS-CoV2 main protease through MM/GBSA.
Bello M; Martínez-Muñoz A; Balbuena-Rebolledo I
J Mol Model; 2020 Nov; 26(12):340. PubMed ID: 33184722
[TBL] [Abstract][Full Text] [Related]
9. Drug designing against NSP15 of SARS-COV2 via high throughput computational screening and structural dynamics approach.
Batool A; Bibi N; Amin F; Kamal MA
Eur J Pharmacol; 2021 Feb; 892():173779. PubMed ID: 33275961
[TBL] [Abstract][Full Text] [Related]
10. Identification of a novel inhibitor of SARS-CoV-2 3CL-PRO through virtual screening and molecular dynamics simulation.
Bepari AK; Reza HM
PeerJ; 2021; 9():e11261. PubMed ID: 33954055
[TBL] [Abstract][Full Text] [Related]
11. Repurposing approved drugs as inhibitors of SARS-CoV-2 S-protein from molecular modeling and virtual screening.
de Oliveira OV; Rocha GB; Paluch AS; Costa LT
J Biomol Struct Dyn; 2021 Jul; 39(11):3924-3933. PubMed ID: 32448085
[TBL] [Abstract][Full Text] [Related]
12. Computational screening of FDA approved drugs of fungal origin that may interfere with SARS-CoV-2 spike protein activation, viral RNA replication, and post-translational modification: a multiple target approach.
Singh R; Gautam A; Chandel S; Sharma V; Ghosh A; Dey D; Roy S; Ravichandiran V; Ghosh D
In Silico Pharmacol; 2021; 9(1):27. PubMed ID: 33842191
[TBL] [Abstract][Full Text] [Related]
13. Drug repurposing studies targeting SARS-CoV-2: an ensemble docking approach on drug target 3C-like protease (3CL
Koulgi S; Jani V; Uppuladinne M; Sonavane U; Nath AK; Darbari H; Joshi R
J Biomol Struct Dyn; 2021 Sep; 39(15):5735-5755. PubMed ID: 32679006
[TBL] [Abstract][Full Text] [Related]
14. Identification of SARS-CoV-2 inhibitors through phylogenetics and drug repurposing.
Mishra A; Mulpuru V; Mishra N
Struct Chem; 2022; 33(5):1789-1797. PubMed ID: 35910782
[TBL] [Abstract][Full Text] [Related]
15. Identification of a potential SARS-CoV2 inhibitor via molecular dynamics simulations and amino acid decomposition analysis.
Razzaghi-Asl N; Ebadi A; Shahabipour S; Gholamin D
J Biomol Struct Dyn; 2021 Oct; 39(17):6633-6648. PubMed ID: 32705953
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive Consensus Analysis of SARS-CoV-2 Drug Repurposing Campaigns.
Mslati H; Gentile F; Perez C; Cherkasov A
J Chem Inf Model; 2021 Aug; 61(8):3771-3788. PubMed ID: 34313439
[TBL] [Abstract][Full Text] [Related]
17. Computational screening for investigating the synergistic regulatory potential of drugs and phytochemicals in combination with 2-deoxy-D-glucose against SARS-CoV-2.
Gupta A; Chauhan SS; Gaur AS; Parthasarathi R
Struct Chem; 2022; 33(6):2179-2193. PubMed ID: 36093277
[TBL] [Abstract][Full Text] [Related]
18. Multi-target direct-acting SARS-CoV-2 antivirals against the nucleotide-binding pockets of virus-specific proteins.
Rani R; Long S; Pareek A; Dhaka P; Singh A; Kumar P; McInerney G; Tomar S
Virology; 2022 Dec; 577():1-15. PubMed ID: 36244310
[TBL] [Abstract][Full Text] [Related]
19. Computationally repurposed drugs and natural products against RNA dependent RNA polymerase as potential COVID-19 therapies.
Piplani S; Singh PK; Winkler DA; Petrovsky N
Mol Biomed; 2021; 2(1):28. PubMed ID: 34766004
[TBL] [Abstract][Full Text] [Related]
20. In silico identification of novel SARS-COV-2 2'-O-methyltransferase (nsp16) inhibitors: structure-based virtual screening, molecular dynamics simulation and MM-PBSA approaches.
El Hassab MA; Ibrahim TM; Al-Rashood ST; Alharbi A; Eskandrani RO; Eldehna WM
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):727-736. PubMed ID: 33685335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
